XWAR
SPH
Market cap245mUSD
Jun 19, Last price
7.50PLN
1D
0.00%
1Q
0.00%
Name
Sopharma AD
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sopharma AD, an international pharmaceutical company founded in Sofia, Bulgaria, in 1933, specializes in the research, development, manufacturing, and commercialization of a wide array of healthcare products. Its offerings span medicinal substances, finished drug formulations, veterinary vaccines, infusion solutions, and disposable plastic medical devices for both human and animal health, in addition to food supplements. The company's diverse product portfolio addresses numerous therapeutic categories, including cardiology, gastroenterology, pain management, cough and cold remedies, immunology and dermatology, respiratory conditions (like asthma), neurology and psychiatry, urology, and gynecology. Key products include Carsil for gastrointestinal issues, the analgesic Tempalgin, Tabex for smoking cessation, Tribestan to support sexual system functions, Broncholytin for coughs, the common pain reliever Analgin, Nivalin for peripheral nervous system disorders, and Methylprednisolon for severe allergies and critical medical situations. Beyond its core pharmaceutical business, Sopharma AD engages in a variety of other ventures. These include providing secondary packaging services for pharmaceuticals, leasing real estate, and operating in the retail sector for medicines and medical equipment. The company also handles the cultivation, collection, and trade of herbs and medicinal plants. Furthermore, it is involved in the trading, transport, and packaging of radioactive materials and nuclear equipment for medical applications, as well as household electronics and electrical equipment. Sopharma AD also offers market and public opinion research, provides franchising and know-how, and participates in various consulting and non-pharmaceutical activities, such as the production of veterinary vaccines and infusion solutions.
Valuation
Title BGN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||